Alnylam Announces Closing of Previously Announced Strategic Alliance with Roche
On July 9, 2007, Alnylam and Roche announced the signing of this alliance in which Roche has obtained a non-exclusive license to Alnylam's technology platform for developing RNAi therapeutics.
Roche is required to make aggregate payments to Alnylam of approximately $331.0 million, including an upfront cash payment within ten business days of the closing in connection with the license.
The Roche Venture Fund purchased 1.975 million shares of Alnylam common stock for an aggregate purchase price of approximately $42.5 million. Roche also completed the acquisition of Alnylam's European research site located in Kulmbach, Germany (Bavaria).